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Dr Paul E. Van Schil (Antwerp, Belgium). I would like to
thank the Association for the privilege of discussing this
excellent paper and I thank the authors for sending me the slides
in advance.
Isolated lung perfusion is an experimental technique to deliver
high-dose chemotherapy to the lung without systemic exposure in
order to obtain better drug targeting. A lot of experimental and,
recently, also clinical studies have been performed to evaluate
toxicity, pharmacokinetics, and efficacy. In fact, 1 of the first
clinical studies originated from Toronto, performed by Michael
Johnston, and published in 1995 in the Journal of Thoracic and
Cardiovascular Surgery. It is stimulating to see that the Toronto
group, having extensive experience with ex vivo lung perfusion,
has picked up experimental in vivo lung perfusion studies again.
The authors are to be congratulated for performing a difficult
experimental study. In our current clinical phase 2 study, which
we perform together with 3 thoracic surgical centers in The
Netherlands, a dose of 45 mg of melphalan is used with a perfusion
time of 30 minutes. In the present experimental study, the authors
demonstrate that in a pig model, perfusion times up to 4 hours are
feasible without any significant lung injury.
I have several questions for the authors and I will list them
separately. Why did you specifically choose Steen solution to
perform the lung perfusion, which is rarely used in clinical in
vivo perfusion studies, in contrast to transplantation?
Dr dos Santos. We used Steen solution because it is a solution
specially developed for lung perfusion and, because of the
increased oncotic pressure, it keeps the water in the intravascular
space and avoids lung edema.rdiovascular Surgery c Volume 147, Number 2 781
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SDr Van Schil. Did you temporarily occlude the arterial
bronchial circulation during perfusion?
Dr dos Santos. Yes. We try to dissect the bronchial circulation
as much as we can, because we noticed that if you do not dissect
and try to ligate these vessels, you are going to have a significant
leak from the bronchial circulation into the pulmonary circulation
and consequently to the circuit, and this might lead to hemody-
namic instability.
DrVan Schil.Regarding the lung injury, howwere the different
scores determined with a range from 0 to 12, and was this a
validated score?
Dr dos Santos. It is an injury score used by our pathologists at
Toronto General Hospital. I’m sorry, I don’t understand the
question.782 The Journal of Thoracic and Cardiovascular SurgDrVan Schil.Regarding the lung injury, youmake a distinction
between scores from 0 to 12. Was this a validated score? We are
very interested in that because we do not have a good scoring
system for lung injury during perfusion.
Dr dos Santos.My feeling is that it is a validated score, because
it is the same score that we have used for many acute lung injury
studies done in our institution. I hope that I’m answering your
question.
Dr Van Schil. Lastly, perfusion was done at normothermia.
Do you have any data on hyperthermic perfusion?
Dr dos Santos.We know that hyperthermia might increase the
uptake of drugs, and probably this is 1 variable that we are plan-
ning for future studies.
Dr Van Schil. Thank you.ery c February 2014
